Comment: Potential risk of valproic acid therapy in patients who are hiv-positive

Annals of Pharmacotherapy

Volumn 34, Issue 11, 2000, Pages 1348-1349

  Jennings, Heath R ^a   Romanelli, Frank ^b  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b University of Kentucky   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIRETROVIRUS AGENT; ANTIVIRUS AGENT; CARBAMAZEPINE; CYTOCHROME P450; GABAPENTIN; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ANTICONVULSANT THERAPY; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; NEUROLOGIC DISEASE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SEIZURE; TREATMENT FAILURE; VIRUS INFECTION;

ANTICONVULSANTS; CYTOMEGALOVIRUS; DRUG INTERACTIONS; HIV SEROPOSITIVITY; HUMANS; NERVOUS SYSTEM DISEASES; VALPROIC ACID; VIRUS REPLICATION;

EID: 0033761576     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.19211a     Document Type: Letter

References (0)